Patients from @ centres in @ countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy , stratified by ECOG performance status , previous bevacizumab treatment , histology , and presence of brain metastases , were allocated ( by computer-generated sequence through an interactive third-party system , in @:@ ratio ) , to receive docetaxel @ mg/m ( @ ) by intravenous infusion on day @ plus either nintedanib @ mg orally twice daily or matching placebo on days @-@ , every @ weeks until unacceptable adverse events or disease progression .